Objectives In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein （CRP） resulting in reduction of cardiovascular events. However, information about discontinuation of statin t...Objectives In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein （CRP） resulting in reduction of cardiovascular events. However, information about discontinuation of statin therapy in stable cardiac patients is limited. This was a prospective cohort study to explore whether withdrawal of statin treatment could result in rebound of inflammation in patients with stable angina pectofis in a short-term course. Methods and Results 75 patients with stable angina pectoris were randomly divided into three groups： ① Pretreatment with Xuezhikang （XZK, an extract of cholestin） for 6 weeks and then replaced by placebo; ②Treatment with XZK throughout the study; ③ Placebo. Lipid levels, highly sensitive CRP （hs-CRP） and serum cardiac troponin T （cTnT） were assessed before receiving the XZK therapy, 1 day before discontinuation of XZK, and on day 1, 2, 3, 7 and 14 after discontinuation of XZK, respectively. At day 14 after discontinuation of XZK therapy, total cholesterol, LDL-C and triglyceride significantly increased, whereas HDL-C level significantly decreased. The median level of hs-CRP increased significantly from the second day after withdrawal of XZK therapy. There was a prominent rebound of hs-CRP concentration 3 days after discontinuation of XZK therapy. 7 to 14 days after discontinuation of XZK therapy, the hs-CRP concentration declined to a similar level as in the placebo group. Elevated eTnT level did not occur throughout the study course in either guroup Conclusios Short-term discontinuation of statin therapy could induce a rapid rebound phenomenon of inflammatory response independently of changes of lipid parameters. However, it was not enough to induce myocardial injury in this cohort of patients with stable angina peetoris.展开更多
文摘Objectives In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein （CRP） resulting in reduction of cardiovascular events. However, information about discontinuation of statin therapy in stable cardiac patients is limited. This was a prospective cohort study to explore whether withdrawal of statin treatment could result in rebound of inflammation in patients with stable angina pectofis in a short-term course. Methods and Results 75 patients with stable angina pectoris were randomly divided into three groups： ① Pretreatment with Xuezhikang （XZK, an extract of cholestin） for 6 weeks and then replaced by placebo; ②Treatment with XZK throughout the study; ③ Placebo. Lipid levels, highly sensitive CRP （hs-CRP） and serum cardiac troponin T （cTnT） were assessed before receiving the XZK therapy, 1 day before discontinuation of XZK, and on day 1, 2, 3, 7 and 14 after discontinuation of XZK, respectively. At day 14 after discontinuation of XZK therapy, total cholesterol, LDL-C and triglyceride significantly increased, whereas HDL-C level significantly decreased. The median level of hs-CRP increased significantly from the second day after withdrawal of XZK therapy. There was a prominent rebound of hs-CRP concentration 3 days after discontinuation of XZK therapy. 7 to 14 days after discontinuation of XZK therapy, the hs-CRP concentration declined to a similar level as in the placebo group. Elevated eTnT level did not occur throughout the study course in either guroup Conclusios Short-term discontinuation of statin therapy could induce a rapid rebound phenomenon of inflammatory response independently of changes of lipid parameters. However, it was not enough to induce myocardial injury in this cohort of patients with stable angina peetoris.
